Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead Ramps Up Remdesivir Manufacturing, Advances Inhaled Formulation

22 Jun 2020

• By Joseph Haas

Daniel O Day — Gilead CEO Daniel O'Day

Related Content

Coronavirus Notebook: Remdesivir Supply Dwindles; US FDA Signs Another RWE Deal; Corning Gets BARDA Contract For Glass Vials

10 Jun 2020

Questions Remain On Gilead’s Remdesivir

01 Jun 2020

Could Gilead Make A Profit From Remdesivir?

23 Apr 2020

Gilead’s Major Challenge Is Sustainable Model For Remdesivir

30 Apr 2020

Gilead's Remdesivir Results Encouraging, Safety Brings Skepticism

29 Apr 2020

Coronavirus Update: Roche Launches Remdesivir Plus Actemra Trial, GSK Plans 1 Billion Vaccine Adjuvant Doses

28 May 2020

NIH Pushes Ahead With First COVID-19 Combo: Remdesivir Plus Lilly’s Olumiant

12 May 2020

Related Companies

Gilead Sciences, Inc.

Eli Lilly and Company

Roche Holding AG

Additional Topics

Coronavirus COVID-19 Clinical Trials Business Strategies Commercial Infectious Diseases BioPharmaceutical

More from COVID-19

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.